Beam Therapeutics Inc. (BEAM)
NASDAQ: BEAM · Real-Time Price · USD
30.19
-0.84 (-2.71%)
At close: Aug 26, 2026, 4:00 PM EDT
30.00
-0.19 (-0.63%)
Pre-market: Aug 27, 2026, 9:01 AM EDT
Beam Therapeutics Employees
Beam Therapeutics had 540 employees as of June 30, 2026. The number of employees increased by 31 or 6.09% compared to the same quarter last year.
Employees
540
Change
31
Growth
6.09%
Revenue / Employee
$288,954
Profits / Employee
-$160,222
Market Cap
3.02B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 540 | 31 | 6.09% |
| Mar 31, 2026 | 522 | 129 | 32.82% |
| Dec 31, 2025 | 511 | 28 | 5.80% |
| Sep 30, 2025 | 510 | 38 | 8.05% |
| Jun 30, 2025 | 509 | 48 | 10.41% |
| Mar 31, 2025 | 393 | 47 | 13.58% |
| Dec 31, 2024 | 483 | 47 | 10.78% |
| Sep 30, 2024 | 472 | 33 | 7.52% |
| Jun 30, 2024 | 461 | -71 | -13.35% |
| Mar 31, 2024 | 346 | -177 | -33.84% |
| Dec 31, 2023 | 436 | -71 | -14.00% |
| Sep 30, 2023 | 439 | -68 | -13.41% |
| Jun 30, 2023 | 532 | 56 | 11.76% |
| Mar 31, 2023 | 523 | 129 | 32.74% |
| Dec 31, 2022 | 507 | 166 | 48.68% |
| Sep 30, 2022 | 507 | 201 | 65.69% |
| Jun 30, 2022 | 476 | 210 | 78.95% |
| Mar 31, 2022 | 394 | 178 | 82.41% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Zai Lab | 1,784 |
| Arcutis Biotherapeutics | 354 |
| Nurix Therapeutics | 317 |
| Viridian Therapeutics | 252 |
| Alumis | 239 |
| Disc Medicine | 165 |
| Precigen | 160 |
| Pharvaris | 148 |
BEAM News
- 20 days ago - Beam Therapeutics price target lowered to $43 from $47 at BofA - TheFly
- 22 days ago - Beam Therapeutics price target raised to $78 from $75 at Canaccord - TheFly
- 23 days ago - Beam Therapeutics reports Q2 EPS ($1.18), consensus ($1.13) - TheFly
- 23 days ago - Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD) - GlobeNewsWire
- 23 days ago - Beam Therapeutics Earnings release: Q2 2026 - Filings
- 23 days ago - Beam Therapeutics Quarterly report: Q2 2026 - Filings
- 5 weeks ago - Beam Therapeutics to Present Updated Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) in Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026 - GlobeNewsWire
- 7 weeks ago - Beam Therapeutics Slides: Conference presentation - Filings